Zogenix Announces Issuance of U.S. Patent for ZX008 in Dravet Syndrome
“This represents the first issued patent covering the treatment of seizures associated with Dravet syndrome using fenfluramine as an adjunctive therapy, and is an important milestone for our ZX008 development program,” said
Zogenix’s Phase 3 program for ZX008 in Dravet syndrome continues to enroll patients in the U.S. and internationally. ZX008 is designated as an orphan drug in both the U.S. and Europe, and also received Fast Track designation in the U.S., for the treatment of Dravet syndrome.
The assignees of this U.S. patent are
For more information, visit www.zogenix.com.
Forward Looking Statements
Andrew McDonaldFounding Partner, LifeSci Advisors LLC646-597-6987 | Andrew@lifesciadvisors.com